Opana ER Should Come Off The US Market, FDA Tells Endo

Agency seeks long-acting opioid’s withdrawal due to evidence the reformulated version increased intravenous abuse; FDA’s action, which Endo is weighing, portends a hard-line stance when it comes to opioid risks under new Commissioner Scott Gottlieb.

The US FDA’s request that Endo Pharmaceuticals Inc. withdraw Opana ER (oxymorphone extended-release) due to its intravenous abuse potential suggests the agency will take a tougher stand on currently marketed opioids under the leadership of newly installed Commissioner Scott Gottlieb.

On June 8, FDA announced it has asked Endo to pull the long-acting opioid from the market because the drug’s...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Drug Safety

More from Pink Sheet